NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

Reference is made to the notice to the stock exchange on 25 January 2010 regarding commencement of subscription period for the “Subsequent offering”. The subscription period ended on 8 February 2010 and mandatory notification of trade among primary insiders of DiaGenic ASA took place. The transactions are described in detail below. Håkon Sæterøy, Executive Chairman of the Board of DiaGenic ASA, has through his companies Investor Corporate AS and Investor Partners AS received 74,802 subscription rights and subscribed for 74,802 shares at NOK 2.75 per share. Sæterøy`s overall exposure in the Company will increase to a total of 1,471,279 shares after allotment of the shares in the issue, in addition to 155,000 warrants (as resolved by the general meeting on 18 December 2009), and in addition to the TRS agreement with exposure for 135,000 shares. Gustav Ingemar Kihlström, Deputy Chairman of the Board of DiaGenic ASA, received 8,956 subscription rights and has subscribed for 8,956 shares in this offering at NOK 2.75 per share. Kihlström`s overall exposure in the Company has increased to a total of 113,956 shares post allotment of the shares in the offering. CEO Erik Christensen has entered into a Total Return equity Swap agreement (TRS) with exposure of 60,000 underlying shares. Expiry date is 7 May 2010, and the TRS price is NOK 3.39 per share. Christensen received 12,795 subscription rights and subscribed for 13,000 shares at NOK 2.75 per share. After allotment of subscribed shares Christensen will increase his exposure by minimum 12,795 shares. Prior to allotment of subscribed shares Christensen directly owns a total of 90,000 shares in addition to the TRS agreement with exposure for 60,000 shares. Praveen Sharma, Director and board member in DiaGenic ASA, received 195,764 subscription rights and has subscribed for 195,764 shares in this offering at NOK 2.75 per share. Sharma’s overall exposure in the Company has increased to a total of 2,490,764 shares post allotment of the shares in the offering in addition to the TRS agreement with exposure for 700,000 shares. Anders Lönneborg, Director in DiaGenic ASA, received 247,370 subscription rights and has sold 240,000 subscription rights at NOK 0.55 per subscription right, and subscribed for 7,370 shares in this offering at NOK 2.75 per share. Lönneborg’s overall exposure in the Company has increased to a total of 2,907,370 shares post allotment of the shares in the offering. Morten Sten Johansen, Director in DiaGenic ASA, received 11,942 subscription rights and has subscribed for 20,000 shares in this offering at NOK 2.75 per share. Johansen’s overall exposure in the Company will increase by minimum 11,942 shares. Prior to the allotment of shares in this offering Johansen owns a total of 140,000 shares in the Company. Dag Christian Christiansen, Director in DiaGenic ASA, received 21,325 subscription rights and has sold 11,325 subscription rights at NOK 0.70 per subscription right, and subscribed for 10,000 shares in this offering at NOK 2.75 per share. Christiansen’s overall exposure in the Company has increased to a total of 260,000 shares post allotment of the shares in the offering. Maria Holmlund, board member in DiaGenic ASA, received 853 subscription rights and has subscribed for 1,000 shares in this offering at NOK 2.75 per share. Holmlund’s overall exposure in the Company will increase by minimum 853 shares. Prior to the allotment of shares in this offering Holmlund owns a total of 10,000 shares in the Company. Ingrid Alfheim, board member in DiaGenic ASA, received 558 subscription rights and has subscribed for 7,000 shares in this offering at NOK 2.75 per share. Alfheim’s overall exposure in the Company will increase by minimum 558 shares. Prior to the allotment of shares in this offering Holmlund owns a total of 6,545 shares in the Company. Torbjørn Lindahl, head of bioinformatics and IT in DiaGenic ASA, received 2,986 subscription rights and has subscribed for 3,000 shares in this offering at NOK 2.75 per share. Lindahl’s overall exposure in the Company will increase by minimum 2,986 shares. Prior to the allotment of shares in this offering Lindahl owns a total of 35,000 shares in the Company. Ruben Ekbråten, Financial Controller in DiaGenic ASA, received 853 subscription rights and has subscribed for 8,000 shares in this offering at NOK 2.75 per share. Ekbråten’s overall exposure in the Company will increase by minimum 853 shares. Prior to the allotment of shares in this offering Ekbråten owns a total of 10,000 shares in the Company. Contact: MD PhD Erik Christensen, CEO Telephone: +47 95939918 e-mail: erik.christensen@diagenic.com